Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 16/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29900502 | 1.00 | NSD2 (0.55) | NSD2TTREDNRAKDM4E | |
| SCHEMBL23092733 | 0.76 | EDNRA (0.53) | EDNRA | |
| SCHEMBL29900464 | 0.76 | EDNRA (0.53) | EDNRA | |
| SCHEMBL2372611 | 0.73 | NSD2 (0.65) | NSD2TTREDNRA | |
| SCHEMBL8893911 | 0.73 | NSD2 (0.70) | NSD2TTREDNRA | |
| SCHEMBL23099921 | 0.72 | CCR8 (0.46) | NSD2EDNRA | |
| SCHEMBL4355524 | 0.71 | CCR8 (0.60) | NSD2KDM4E | |
| SCHEMBL20103064 | 0.71 | ALDH1A1 (0.48) | KDM4E | |
| SCHEMBL4455048 | 0.70 | CA1 (0.57) | NSD2TTRKDM4E | |
| SCHEMBL21878809 | 0.70 | NSD2 (1.00) | NSD2TTREDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4028385-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | NSD2 1033/4885TTR 3779/4885EDNRA 4385/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | NSD2 1033/4885TTR 3779/4885EDNRA 4385/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | NSD2 1033/4885TTR 3779/4885EDNRA 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.